**Melanoma Margins Trial-II** is a study for patients with *stage II primary cutaneous melanoma*, a type of skin cancer. This study compares two surgical margin sizes: **1 cm** and **2 cm**. A *margin* is the area of healthy skin removed around the tumor to ensure all cancer cells are excised. Researchers want to see if a smaller margin is just as safe and improves *quality of life* by reducing surgery side effects and complications. Key Points: - Participation requires being an adult with stage II melanoma and a life expectancy of at least 5 years (not counting the melanoma). - Surgery must occur within 120 days of diagnosis, and within 28 days of joining the study. - The study evaluates how these margins affect recurrence risks and economic impacts. Patients cannot join if they have uncertain melanoma diagnosis, certain types of melanoma (like *desmoplastic melanoma*), past melanoma surgeries at the study site, or have had other cancers within the last 5 years (except some skin cancers). Those on certain medications or with specific medical histories, like organ transplants, are also excluded. Pregnant women need special consideration and potential delay in participation.